

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Tasmar (tolcapone)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Quantity Limit
Tasmar (tolcapone)	N/A

APPROVAL CRITERIA

Requests for Tasmar (tolcapone) may be approved if the following criteria are met:

- I. Individual is using for the symptomatic treatment of Parkinsonian syndrome; **AND**
- II. Individual is using concomitantly with carbidopa/levodopa therapy; **AND**
- III. Individual is not responding satisfactorily to, or is not an appropriate candidate for other adjunctive therapies.

Note: Tasmar (tolcapone) has a black box warning for the risk of potentially fatal, acute fulminant liver failure. Because of the risk of liver injury and because Tasmar, when it is effective, provides an observable symptomatic benefit, the individual who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from Tasmar. Tasmar therapy should not be initiated if the individual exhibits clinical evidence of liver disease or two serum glutamic-pyruvic transaminase/alanine aminotransferase (SGPT/ALT) or serum glutamic-oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) values greater than the upper limit of normal. Individuals with severe dyskinesia

PAGE 1 of 2 11/22/2016

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

WEB-PEC-0517-16

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

or dystonia should be treated with caution and those who develop evidence of hepatocellular injury while on the medication and are withdrawn from the drug for any reason may be at increased risk for liver injury if the medication is reintroduced. Accordingly, such individuals should not ordinarily be considered for retreatment.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2016. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2016; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.